ID   PC9-DPE2
AC   CVCL_S977
DR   cancercelllines; CVCL_S977
DR   Wikidata; Q54938602
RX   PubMed=9052401;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 3148; TYMP.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 16
//
RX   PubMed=9052401; DOI=10.1038/bjc.1997.88;
RA   Kato Y., Matsukawa S., Muraoka R., Tanigawa N.;
RT   "Enhancement of drug sensitivity and a bystander effect in PC-9 cells
RT   transfected with a platelet-derived endothelial cell growth factor
RT   thymidine phosphorylase cDNA.";
RL   Br. J. Cancer 75:506-511(1997).
//